All > Gestational Diabetes > Diabetes Type 2

Glycemic Control Financial Incentive for Diabetes Mellitus, Type 2

Phase-Based Progress Estimates

Effectiveness

Safety

Medical College of Wisconsin, Milwaukee, WI

Diabetes Mellitus, Type 2+1 More

Glycemic Control Financial Incentive - Behavioral

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18+

All Sexes

What conditions do you have?

Select

Eligibility

18+

All Sexes

What conditions do you have?

Select

Study Summary

This trial will test if financial incentives can help improve HbA1c, blood pressure, and quality of life in food insecure adults with type 2 diabetes. The Glycemic Control Financial Incentive is being used to treat Diabetes Mellitus, Type 2. This is a condition where the body does not produce enough insulin, or the cells do not respond properly to insulin. This can lead to high blood sugar levels. The Glycemic Control Financial Incentive has been previously approved by the FDA for a different condition. However, this is the first time that it has been tested on patients with Diabetes Mellitus, Type 2. No patients in this trial will receive a placebo.

Eligible Conditions

Diabetes Mellitus, Type 2

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Diabetes Mellitus, Type 2

Financial Incentive

Personalized

Financial Incentive

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 6-months post randomization

6-months post randomization

Blood pressure (both systolic and diastolic)

Glycemic control (HbA1c)

Quality of life as measured by the Short Form Health Survey (SF-12)

Trial Safety

Safety Progress

1 of 3

Other trials for Diabetes Mellitus, Type 2

Financial Incentive

Personalized

Financial Incentive

Trial Design

3 Treatment Groups

Monthly Unconditional Financial Incentive

1 of 3

Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financi...

1 of 3

Monthly Unconditional Plus Healthy Food Purchasing Financial Incentive

1 of 3

Experimental Treatment

150 Total Participants · 3 Treatment Groups

Primary Treatment: Glycemic Control Financial Incentive · No Placebo Group · N/A

Monthly Unconditional Financial IncentiveExperimental Group · 2 Interventions: Monthly Unconditional Financial Incentive, Diabetes Education · Intervention Types: Behavioral, Behavioral

Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial IncentiveExperimental Group · 4 Interventions: Weekly Food Purchasing Financial Incentive, Monthly Unconditional Financial Incentive, Diabetes Education, Glycemic Control Financial Incentive · Intervention Types: Behavioral, Behavioral, Behavioral, Behavioral

Monthly Unconditional Plus Healthy Food Purchasing Financial IncentiveExperimental Group · 3 Interventions: Weekly Food Purchasing Financial Incentive, Monthly Unconditional Financial Incentive, Diabetes Education · Intervention Types: Behavioral, Behavioral, Behavioral

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Diabetes Education

2019

Completed Phase 3

~2550

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: 6-months post randomization

Closest Location: Medical College of Wisconsin · Milwaukee, WI

2006First Recorded Clinical Trial

7 TrialsResearching Diabetes Mellitus, Type 2

564 CompletedClinical Trials

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor

547 Previous Clinical Trials

1,150,435 Total Patients Enrolled

11 Trials studying Diabetes Mellitus, Type 2

551,332 Patients Enrolled for Diabetes Mellitus, Type 2

Rebekah J Walker, PhDPrincipal InvestigatorMedical College of Wisconsin

1 Previous Clinical Trials

300 Total Patients Enrolled

1 Trials studying Diabetes Mellitus, Type 2

300 Patients Enrolled for Diabetes Mellitus, Type 2

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

You must be at least 21 years old to be screened.

About The Reviewer

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References